Neogen

NEOGNasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$2.968 B

$13.61 +4.69%

Close of 21 Sept 2026

Revenue

$870.4M

#1601 by revenue

Earnings

-$7.90M

Loss-making

Shares outstanding

218,056,016

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#3Oruka TherapeuticsORKA$6.18B
#4Celldex TherapeuticsCLDX$2.98B
#5NeogenNEOG$2.97B
#6Intellia TherapeuticsNTLA$1.71B
#7Achieve Life SciencesACHV$828.4M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Neogen, worth $4.37K. Grants and option exercises are excluded.

Mikheal NassifCEO$4.37K
370 shares at $11.81 on 4 Aug 2026 · filed 6 Aug 2026

What if Neogen were worth as much as…

Open the what-if tool →

Gold $30.3T

$138,804.31

Per share 10,199× higher

Bitcoin $1.72T

$7,885.17

Per share 579× higher

Nvidia $5.48T

$25,124.75

Per share 1,846× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Neogen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.